9 Canadian FemTech innovators transforming women’s health
From pelvic health to neuromodulation and data innovation
Canada’s women’s health innovation ecosystem has accelerated rapidly in the past five years, producing a wave of clinically grounded, technically sophisticated and culturally-aware startups. From personalised gynaecology devices to neuromodulation, AI-enabled diagnostics and Indigenous-led data innovation, these companies exemplify the breadth and ambition of the sector.
FutureFemHealth sat down to speak with nine Canadian FemTech startups each transforming women’s health:
1. Cosm Medical — Precision gynaecology and the “Invisalign for pelvic health”
Cosm Medical is pioneering personalised pessaries and next-generation tissue remodelling devices for pelvic floor conditions — one of the most neglected areas of women’s health. With almost 10 million potential shape combinations on its 3D printing platform, the company aims to replace today’s trial-and-error fittings with precision-engineered care. Now they are in clinical studies for the first applications of tissue remodeling with a mechanical gynaecological device to help women recover from surgery and childbirth. Founder and CEO Derek Sham explains the goal: “We’re essentially bringing precision into this field — first with personalised pessaries, and then by unlocking tissue remodelling to help women recover from surgery and childbirth.”
👉 Read our full interview with Cosm Medical
2. Juno Technologies — taking on menstrual pain with a medical device
Montreal-based Juno is developing a connected neuromodulation device to help women manage severe menstrual pain — a condition too often normalised or dismissed. Their device is being built with clinicians from day one, with regulatory pathways already underway for FDA and Health Canada. As co-founder Nanette Sene puts it: “Reducing pain is kind of the best thing you can do… If you’re creating a solution that’s reducing people’s pain, there is not much better satisfaction than that.”
👉 Read our full interview with Juno Technologies
3. Emovi — 3D knee-motion analysis transforming women’s knee health
Emovi’s KneeKG system captures real-time 3D knee motion — offering insights far beyond what traditional static imaging can deliver. Originally developed for osteoarthritis, it is now used across sports medicine, rehabilitation and preventive care. With women up to four times more likely to suffer ACL injuries, the implications for female athletes and older women are significant. “Every knee has a pattern,” explains Europe director Yann Lamarche. “When that pattern shifts… that’s when injury risk increases.”
👉 Read our full interview with Emovi
4. My Normative — Closing the sex and gender data gap through culturally-grounded research
My Normative is reshaping how sex- and gender-specific health data is captured and interpreted — and is now leading an Indigenous-community partnership on gestational diabetes with Enoch Cree Nation Sovereign Health and Health Cities. The work focuses on sovereignty, cultural context and methodological rigour rather than extraction. CEO Danika Kelly says: “If we’re asking communities to trust us, we have to build processes that respect how they understand time, health, risk and experience.”
👉 Read our full interview with My Normative
5. Mino Care — Culturally-safe maternity care built for real-world outcomes
Mino Care, founded by Elsie Amoako, is redefining maternity support by embedding culturally informed perinatal care alongside clinical services. Operating as a virtual reproductive health centre, it links hospitals and clinics with doulas, lactation consultants, pelvic-floor therapists, mental health counsellors and more — all selected for both clinical expertise and cultural understanding. With referrals from 20+ Canadian healthcare institutions, Mino Care is demonstrating measurable impact in reducing gaps between the clinic and the home. As Amoako puts it: “We make sure that women and birthing persons have the safest and most culturally safe experiences possible… Care can literally be the difference between life and death.”
👉 Read our full interview with Mino Care
6. Cogni Corp+ Therapies — Early mental-health intervention built around the whole person
Founded by mental-health practitioner Emmanuella Michel, Cogni Corp+ Therapies helps providers act earlier by transforming intake notes into data-driven wellbeing insights across what Michel calls the eight dimensions of wellbeing. Not diagnostic but deeply supportive, the platform gives clinicians and employers a way to offer personalised, culturally attuned early intervention rather than waiting for crisis. “We often wait until there’s a fire before putting preventive measures in place,” Michel says. Her lived experience with postpartum depression shaped the product’s mission: to fill the gap between sessions, help people stay engaged in care, and give workplaces practical tools to reduce burnout. With early contracts including Health Canada, Cogni Corp+ is now exploring UK and French pilots as it raises a seed round.
👉 Read our full interview with Cogni Corp+ Therapies
7. SYNG Pharma’s EndoID — A decade-long mission to deliver a simple, accessible test for endometriosis
For ten years, researcher-turned-founder Vinay Singh has been driven by a conviction that endometriosis deserves a fast, affordable diagnostic. “I would walk into investor rooms full of men who had never even heard of endometriosis,” he recalls — yet he kept going, funding the science himself when needed. Today, SYNG Pharma’s diagnostic EndoID has secured regulatory approval in India, with commercial rollout beginning in early 2026 and trials under way in Canada. EndoID is a dual-biomarker test using serum or menstrual blood to detect molecular signals of the disease, offering a non-invasive first-line screen that could drastically shorten diagnosis times. “For a 14, 15-year-old young girl who would not go for invasive procedure… we wanted to have an accessible and affordable solution,” Singh says. CE-marking and UK partnerships are next, alongside development of a future lateral-flow test using a single drop of blood — the next step in a mission Singh describes as “deeply personal and close to me.”
👉 Read our full interview with SYNG Pharma
8. Elan Healthcare — Doctor-led supplements targeting PCOS, fertility and menopause
Founded in 2016 by family doctor Dr Pari Saharkhiz and pharmaceutical scientist Dr Rasoul Soleimani, Elan Healthcare develops condition-specific, evidence-based supplements for PCOS, fertility, menopause and andropause. “We don’t do generic multivitamins,” Saharkhiz says. “Our products are very focused on specific conditions.” Her clinical background shaped the company’s prevention-first ethos: despite PCOS affecting millions, she notes it still receives little medical training and many women remain undiagnosed. For Saharkhiz, oral contraceptives often miss the root issue. “The problem is insulin resistance, not the ovaries,” she says. Elan’s formulations are grounded in clinical literature, reviewed by Health Canada, and expanded based on patient demand — with products for endometriosis and sperm motility expected next year. Bridging wellness and clinical insight, Saharkhiz sees supplements as part of a wider shift toward earlier, gentler interventions: “We need the drugs and surgeries, but there are ways to plan and prevent before we get there.”
👉 Read our full interview with Elan Healthcare
9. Neuraura’s LoOop — Bringing the first potential new PCOS treatment in 70 years
For a condition affecting up to one in five women, PCOS has seen no new treatment options in more than seventy years. Neuraura, led by CEO Claire Dixon, is aiming to change that with LoOop, a combined digital platform and at-home neuromodulation device intended to regulate glucose, improve menstrual cycles and enhance ovarian blood flow. While regulatory clearance is still ahead, LoOop is the first attempt to bring a clinical-grade, non-pharmaceutical intervention for PCOS directly into the home. The companion app offers symptom and medication tracking, clinically validated journalling, and over 600 pages of evidence-backed content — all designed to help users communicate effectively with clinicians and manage PCOS as the whole-body condition it is. “You’d never dream of telling someone with diabetes or arthritis to come back when they want to get pregnant,” Dixon says. “But that’s still the standard response for PCOS.” Originating from electrostimulation research inspired by Dr Stener-Victorin, Neuraura is preparing FDA filings for 2026 and raising a $2m seed round to accelerate pilot data. For Dixon, the mission is straightforward: “We have the first new treatment option for PCOS in seventy years. Now we just need the support to get it to market.”
👉 Read our full interview with Neuraura
Each of the startups featured in this article have been selected for the 2025 Canadian Technology Accelerator (CTA) FemTech program organised by the Government of Canada. This program is free for the selected participants, and it provides access to mentors, a peer network, masterclasses delivered by subject matter experts on topics like the market landscape, IP considerations, fund raising, regulatory issues, public relations, and more, and a dedicated visit to the UK and France to connect founders with potential partners and customers. This article is part of a partnership with the High Commission Canada in the UK.